Display options
Cite
Yamaguchi Y, Lee YA, Goto Y. Dopamine in socioecological and evolutionary perspectives: implications for psychiatric disorders. Front Neurosci. 2015;9:219doi: 10.3389/fnins.2015.00219.
Yamaguchi, Y., Lee, Y. A., & Goto, Y. (2015). Dopamine in socioecological and evolutionary perspectives: implications for psychiatric disorders. Frontiers in neuroscience, 9219. https://doi.org/10.3389/fnins.2015.00219
Yamaguchi, Yoshie, et al. "Dopamine in socioecological and evolutionary perspectives: implications for psychiatric disorders." Frontiers in neuroscience vol. 9 (2015): 219. doi: https://doi.org/10.3389/fnins.2015.00219
Yamaguchi Y, Lee YA, Goto Y. Dopamine in socioecological and evolutionary perspectives: implications for psychiatric disorders. Front Neurosci. 2015 Jun 16;9:219. doi: 10.3389/fnins.2015.00219. eCollection 2015. PMID: 26136653; PMCID: PMC4468839.
Copy Download .nbib Format: NLM
Share it on

Front Neurosci. 2015 Jun 16;9:219. doi: 10.3389/fnins.2015.00219. eCollection 2015.

Dopamine in socioecological and evolutionary perspectives: implications for psychiatric disorders.

Frontiers in neuroscience

Yoshie Yamaguchi, Young-A Lee, Yukiori Goto

Affiliations

  1. Section of Cognition and Learning, Department of Cognitive Science, Primate Research Institute, Kyoto University Inuyama, Japan.
  2. Department of Food Science and Nutrition, Catholic University of Daegu Gyeongsan-Si, Korea.

PMID: 26136653 PMCID: PMC4468839 DOI: 10.3389/fnins.2015.00219

Abstract

Dopamine (DA) transmission in brain areas such as the prefrontal cortex (PFC) and nucleus accumbens (NAcc) plays important roles in cognitive and affective function. As such, DA deficits have been implicated in a number of psychiatric disorders such as schizophrenia and attention deficit/hyperactivity disorder (ADHD). Accumulating evidence suggests that DA is also involved in social behavior of animals and humans. Although most animals organize and live in social groups, how the DA system functions in such social groups of animals, and its dysfunction causes compromises in the groups has remained less understood. Here we propose that alterations of DA signaling and associated genetic variants and behavioral phenotypes, which have been normally considered as "deficits" in investigation at an individual level, may not necessarily yield disadvantages, but even work advantageously, depending on social contexts in groups. This hypothesis could provide a novel insight into our understanding of the biological mechanisms of psychiatric disorders, and a potential explanation that disadvantageous phenotypes associated with DA deficits in psychiatric disorders have remained in humans through evolution.

Keywords: dopamine; evolution; genetic variants; primates; psychiatric disorder; social hierarchy; social interaction

References

  1. Psychopharmacology (Berl). 2014 Apr;231(8):1503-15 - PubMed
  2. Sci Rep. 2013;3:1042 - PubMed
  3. Comp Biochem Physiol A Comp Physiol. 1987;87(2):261-5 - PubMed
  4. Nature. 1997 Feb 13;385(6617):634-6 - PubMed
  5. Biol Psychiatry. 1980 Dec;15(6):829-39 - PubMed
  6. Am J Hum Genet. 2002 Dec;71(6):1296-302 - PubMed
  7. Behav Pharmacol. 2011 Aug;22(4):300-11 - PubMed
  8. Biol Psychiatry. 2008 Jul 15;64(2):137-44 - PubMed
  9. Neuropsychopharmacology. 2013 Apr;38(5):701-14 - PubMed
  10. Neuroscience. 2013 Jan 3;228:83-100 - PubMed
  11. Trauma Violence Abuse. 2006 Jan;7(1):19-33 - PubMed
  12. Psychopharmacology (Berl). 2004 Nov;176(3-4):331-42 - PubMed
  13. Addict Behav. 2014 Nov;39(11):1632-9 - PubMed
  14. Nat Genet. 2008 Jul;40(7):827-34 - PubMed
  15. Curr Biol. 2015 Mar 30;25(7):912-9 - PubMed
  16. Mol Psychiatry. 1998 May;3(3):261-5 - PubMed
  17. Neuroimage. 2010 Mar;50(1):323-8 - PubMed
  18. Drugs. 2011 May 7;71(7):827-40 - PubMed
  19. Am J Psychiatry. 2012 Mar;169(3):264-72 - PubMed
  20. Science. 1991 Feb 22;251(4996):947-50 - PubMed
  21. Psychopharmacology (Berl). 2004 Jun;174(1):86-98 - PubMed
  22. Neuroreport. 1999 Sep 9;10(13):2789-93 - PubMed
  23. Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6917-22 - PubMed
  24. Nature. 2014 Jul 24;511(7510):421-7 - PubMed
  25. Prog Neurobiol. 2004 Dec;74(5):301-20 - PubMed
  26. J Exp Biol. 2014 May 1;217(Pt 9):1496-503 - PubMed
  27. Nat Rev Genet. 2012 Jul 18;13(8):565-75 - PubMed
  28. Front Neurosci. 2013 Nov 05;7:201 - PubMed
  29. Br J Psychiatry. 1987 May;150:598-608 - PubMed
  30. Schizophr Res. 1998 Sep 7;33(1-2):53-61 - PubMed
  31. Psychopharmacology (Berl). 2013 Jul;228(1):167-74 - PubMed
  32. Cell. 2014 Jun 19;157(7):1535-51 - PubMed
  33. Neuroimage. 2014 Nov 15;102 Pt 2:590-5 - PubMed
  34. Philos Trans R Soc Lond B Biol Sci. 2010 Dec 27;365(1560):4021-8 - PubMed
  35. Prog Neurobiol. 1998 Jul;55(4):343-61 - PubMed
  36. Am J Hum Genet. 2010 Sep 10;87(3):316-24 - PubMed
  37. J Affect Disord. 2012 Feb;136(3):229-37 - PubMed
  38. Proc Natl Acad Sci U S A. 2011 Feb 1;108(5):1993-7 - PubMed
  39. Neuropsychopharmacology. 2006 Nov;31(11):2376-83 - PubMed
  40. Ann N Y Acad Sci. 2008;1129:200-12 - PubMed
  41. J Exp Biol. 2015 Apr;218(Pt 7):1091-8 - PubMed
  42. Synapse. 2008 Oct;62(10):715-24 - PubMed
  43. Brain Res. 2003 Apr 25;970(1-2):1-8 - PubMed
  44. Ann Hum Biol. 2009 Sep-Oct;36(5):562-72 - PubMed
  45. J Neurosci. 2010 Apr 21;30(16):5730-43 - PubMed
  46. Nat Neurosci. 2002 Feb;5(2):169-74 - PubMed
  47. Neuropsychopharmacology. 2006 Feb;31(2):297-309 - PubMed
  48. Hum Mol Genet. 2006 Jul 15;15(14):2276-84 - PubMed
  49. Br Med J. 1955 May 14;1(4923):1189-91 - PubMed
  50. Nicotine Tob Res. 2009 Jan;11(1):64-76 - PubMed
  51. Mol Psychiatry. 2005 Aug;10(8):765-70 - PubMed
  52. Int J Epidemiol. 2009 Oct;38(5):1224-34 - PubMed
  53. Schizophr Bull. 2012 Sep;38(5):958-66 - PubMed
  54. Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17377-81 - PubMed
  55. Arch Insect Biochem Physiol. 2005 Jul;59(3):103-17 - PubMed
  56. Psychol Bull. 2007 Sep;133(5):833-58 - PubMed
  57. Synapse. 1987;1(2):133-52 - PubMed
  58. J Neurosci. 2008 Dec 31;28(53):14372-8 - PubMed
  59. Pharmacogenetics. 1997 Dec;7(6):479-84 - PubMed
  60. Neuropsychopharmacology. 1989 Sep;2(3):191-9 - PubMed
  61. Int J Addict. 1982 Oct;17(7):1185-209 - PubMed
  62. Behav Neurosci. 1983 Aug;97(4):595-601 - PubMed
  63. Br J Psychiatry. 2007 Mar;190:194-9 - PubMed
  64. Indian J Physiol Pharmacol. 1997 Jul;41(3):219-26 - PubMed
  65. Exp Brain Res. 2000 Jul;133(1):130-8 - PubMed
  66. Nat Rev Genet. 2012 Jul 10;13(8):537-51 - PubMed
  67. Behav Brain Res. 2004 Jan 5;148(1-2):185-98 - PubMed
  68. Nat Neurosci. 2004 Aug;7(8):847-54 - PubMed
  69. Neuropsychopharmacology. 2007 Feb;32(2):273-83 - PubMed
  70. Biol Psychiatry. 2005 Jan 15;57(2):167-72 - PubMed
  71. Neuropsychopharmacology. 2008 May;33(6):1441-52 - PubMed
  72. Neuropsychopharmacology. 2005 Oct;30(10):1883-94 - PubMed
  73. J Neurosci. 1997 Nov 1;17(21):8528-35 - PubMed
  74. Public Health Rep. 2002;117 Suppl 1:S104-17 - PubMed
  75. Mol Psychiatry. 2007 May;12(5):454-61 - PubMed
  76. J Formos Med Assoc. 2010 Oct;109 (10 ):736-9 - PubMed
  77. Neuroscience. 2009 Feb 18;158(4):1257-65 - PubMed
  78. Trends Cogn Sci. 2014 Apr;18(4):194-202 - PubMed
  79. Adv Pharmacol. 1998;42:655-70 - PubMed
  80. Schizophr Bull. 2009 May;35(3):549-62 - PubMed
  81. Neuroimage. 2001 May;13(5):891-5 - PubMed
  82. J Nerv Ment Dis. 1991 Aug;179(8):507-8 - PubMed
  83. Neuropsychopharmacology. 2002 Apr;26(4):431-43 - PubMed
  84. Biol Psychiatry. 2012 Sep 1;72(5):414-21 - PubMed
  85. Brain Res. 1991 Sep 20;559(2):181-90 - PubMed
  86. Int J Mol Epidemiol Genet. 2012;3(2):115-21 - PubMed
  87. J Neurochem. 2007 Feb;100(4):1047-61 - PubMed
  88. Int J Neuropsychopharmacol. 2013 Sep;16(8):1819-34 - PubMed
  89. Mol Psychiatry. 2003 Nov;8(11):911-5 - PubMed
  90. Psychopharmacology (Berl). 2014 Apr;231(7):1409-16 - PubMed
  91. J Psychopharmacol. 2012 Jun;26(6):794-805 - PubMed
  92. Alcohol Clin Exp Res. 1993 Apr;17(2):199-204 - PubMed
  93. JAMA Psychiatry. 2013 Jan;70(1):22-30 - PubMed
  94. Rev Neurosci. 2008;19(2-3):83-9 - PubMed
  95. Mol Psychiatry. 1996 May;1(2):121-4 - PubMed
  96. J Neurosci. 1998 Apr 1;18(7):2720-8 - PubMed
  97. Nat Neurosci. 2006 Jan;9(1):133-9 - PubMed
  98. PLoS One. 2008 Apr 09;3(4):e1974 - PubMed
  99. J Abnorm Psychol. 2005 Nov;114(4):599-611 - PubMed
  100. Am J Psychiatry. 2002 May;159(5):761-7 - PubMed
  101. Cold Spring Harb Symp Quant Biol. 1964;29:137-49 - PubMed
  102. PLoS One. 2012;7(9):e44275 - PubMed
  103. Am Nat. 1998 Feb;151(2):148-56 - PubMed
  104. Mol Biol Evol. 2008 Jan;25(1):18-28 - PubMed
  105. Front Neurosci. 2011 Jun 21;5:81 - PubMed
  106. Ann N Y Acad Sci. 1998 May 15;839:47-52 - PubMed
  107. Am J Psychiatry. 2003 Mar;160(3):469-76 - PubMed
  108. Psychopharmacology (Berl). 2000 Aug;151(2-3):99-120 - PubMed
  109. Am J Med Genet. 2000 Spring;97(1):52-7 - PubMed
  110. Neuropsychopharmacology. 2001 Oct;25(4):498-504 - PubMed
  111. Schizophr Res. 2008 Mar;100(1-3):302-7 - PubMed
  112. Arch Gen Psychiatry. 2003 Sep;60(9):889-96 - PubMed
  113. Biol Psychiatry. 2010 Feb 1;67(3):275-8 - PubMed
  114. J Neurosci. 2014 Aug 6;34(32):10616-23 - PubMed
  115. Neurochem Res. 2003 Jan;28(1):73-82 - PubMed
  116. J Am Acad Child Adolesc Psychiatry. 1997 Dec;36(12):1672-9; discussion 1679-81 - PubMed
  117. Front Neurosci. 2012 Feb 06;6:9 - PubMed
  118. Curr Opin Neurobiol. 2013 Apr;23(2):229-38 - PubMed
  119. Schizophr Res. 2003 May 1;61(1):31-7 - PubMed
  120. Psychopharmacology (Berl). 2006 Nov;188(4):586-96 - PubMed
  121. Mol Psychiatry. 2007 May;12(5):502-9 - PubMed
  122. MMWR Morb Mortal Wkly Rep. 2010 Nov 12;59(44):1439-43 - PubMed
  123. Pharmacol Biochem Behav. 1993 Aug;45(4):765-76 - PubMed
  124. Psychopharmacology (Berl). 2010 Mar;208(4):585-92 - PubMed
  125. Am J Psychiatry. 1999 Sep;156(9):1358-66 - PubMed
  126. Science. 2008 Jun 20;320(5883):1629-31 - PubMed

Publication Types